NCT04803929View on ClinicalTrials.gov

Clinical Study of Anti-ILT3 CAR-T Therapy for R/R AML(M4/M5)

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

March 3, 2021

Primary Completion Date

March 1, 2024

Study Completion Date

March 1, 2026

Conditions
AML M4AML M5
Interventions
BIOLOGICAL

anti-ILT3 CAR-T

Autologous T cells genetically modified with anti-ILT3 CAR

Trial Locations (1)

Unknown

RECRUITING

Zhejiang Provincal People's Hospital, Hangzhou

Sponsors
All Listed Sponsors
collaborator

Zhejiang Provincial People's Hospital

OTHER

lead

Carbiogene Therapeutics Co. Ltd.

INDUSTRY